Phase 4Status unknown
A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese
A Randomized,Active-controlled,Open-label Clinical Trial to Evaluate the Effect of GLP-1 Receptor Agonist (Exenatide Injection) in Combination With Metformin Therapy Compared to Premixed Insulin (BIAsp30) in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese
- Sponsor
- The First Hospital of Jilin University (Academic or other)
- Enrollment
- 200 planned
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide; BIAsp30; Metformin
- Ages
- adults, older adults
- Registry
- NCT03018665
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese
Primary outcomes
- Rate of Inducing Diabetes Remission
- Change of Rate of Maintaining Diabetes Remission
- Time of Maintaining Diabetes Remission
History
Primary completion
Started
Registered